Acute myocardial infarction on the background of feminizing hormone therapy

Authors: Buziashvili Yu.I., Asymbekova E.V., Tugeeva E.F., Shuvaev I.P., Golubev E.P., Akildzhonov F.R.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Case reports


DOI: https://doi.org/10.24022/1997-3187-2023-17-1-153-159

For citation: Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F., Shuvaev I.P., Golubev E.P., Akildzhonov F.R. Acute myocardial infarction on the background of feminizing hormone therapy. Creative Cardiology. 2023; 17 (1): 153–9 (in Russ.). DOI: 10.24022/1997-3187-2023-17-1-153-159

Received / Accepted:  11.09.2022 / 14.02.2023

Keywords: acute myocardial infarction transgender feminizing hormone therapy

Download
Full text:  

 

Abstract

The prevalence of the transgender population worldwide is steadily increasing. Due to the complex interplay between underlying disease, psychosocial factors, and high doses of hormone replacement therapy, transgender patients present a diagnostic and therapeutic challenge. This case presents one of such dilemmas on the example of a clinical analysis of acute transmural myocardial infarction against the background of feminizing hormone therapy. The clinical case emphasizes the need for a differential diagnostic search in young patients with complaints of pain in the heart area against the background of feminizing hormone therapy. In the diagnostic search for a probable cause, it was not possible to determine the main provoking factor for the manifestation of acute transmural myocardial infarction with a debut at an early age. An important factor now, apparently, is high-dose hormonal therapy for gender conversion, which is associated with the activation of the thrombotic cascade with further hypercoagulability and the development of a cardiovascular complication.

References

  1. Meerwijk E., Sevelius J. Transgender population size in the united states: a meta-regression of population-based probability samples. Am. J. Public Health. 2017; 107 (2): e1–e8. DOI: 10.2105/ AJPH.2016.303578
  2. Abramowitz J. Hormone Therapy in Children and Adolescents. Endocrinol. Metab. Clin. North Am. 2019; 48 (2): 331–9. DOI: 10.1016/j.ecl.2019. 01.003
  3. The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) 2017. ESC guidelines for the management of acute myocardial infarction in pati-ents presenting with ST-segment elevation. Russian Journal of Cardiology. 2018; 5: 103–58 (in Russ.). DOI: 10.15829/1560-4071-2018-5- 103-158
  4. Alzahrani T., Nguyen T., Ryan A. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ. Cardiovasc. Qual. Outcomes. 2019; 12 (4): e005597. DOI: 10.1161/ CIRCOUTCOMES.119.005597
  5. Totaro M., Palazzi S., Castellini C. Risk of venous thromboembolism in transgender people undergoing hormone feminizing therapy: a prevalence meta-analysis and meta-regression study. Front. Endocrinol (Lausanne). 2021; 12: 741866. DOI: 10.3389/fendo.2021.741866
  6. Hughes L., King W., Gamarel K., Geronimus A., Panagiotou O., Hughto J. Differences in all-cause mortality among transgender and non-transgender people enrolled in private insurance. Demography. 2022; 59 (3): 1023–43. DOI: 10.1215/00703370- 9942002
  7. Asscheman H., T'Sjoen G., Lemaire A. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia. 2014; 46 (7): 791–5. DOI: 10.1111/and.12150
  8. Dutra E., Lee J., Torbati T., Garcia M., Merz C., Shufelt C. Cardiovascular implications of genderaffirming hormone treatment in the transgender population. Maturitas. 2019; 129: 45–9. DOI: 10.1016/j.maturitas.2019.08.010
  9. Maraka S., Singh Ospina N., Rodriguez-Gutierrez R. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2017; 102 (11): 3914-23. DOI: 10.1210/jc.2017-01643
  10. Aranda G., Halperin I., Gomez-Gil E. Cardiovascular risk associated with gender affirming hormone therapy in transgender population. Front. Endocrinol. (Lausanne). 2021; 12: 718200. DOI: 10.3389/fendo.2021.718200
  11. Kim J., Bhupathiraju S., Harrington L. Oral postmenopausal hormone therapy and genetic risk on venous thromboembolism: gene-hormone interaction results from a large prospective cohort study. Menopause. 2022; 29 (3): 293-303. DOI: 10.1097/ GME.0000000000001924
  12. Wierckx K., Van Caenegem E., Schreiner T., Haraldsen I., Fisher A., Toye K. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the european network for the investigation of gender incongruence. J. Sex. Med. 2014; 11 (8): 1999–2011. DOI: 10.1111/jsm.12571
  13. Nota Nienke M., Wiepjes C., de Blok C., Gooren L., Kreukels B., den Heijer M. Ocurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation. 2019; 139 (11): 1461–2. DOI: 10.1016/j.endinu.2018.11.004
  14. Nokoff N., Scarbro S., Juarez-Colunga E., Moreau K, Kempe A. Health and cardiometabolic disease in transgender adults in the United States: behavioral risk factor surveillance system 2015. J. Endocr. 2018; 2 (4): 349–60. DOI: 10.1097/ MED.0000000000000064
  15. Seal L.J. Cardiovascular disease in transgendered people: A review of the literature and discussion of risk. JRSM Cardiovasc. Dis. 2019; 8: 2048004019880745. DOI: 10.1177/2048004019880745
  16. Schutte M., Kleemann R., Nota N. The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis. PLoS One. 2022; 17 (3): e0261312. DOI: 10.1371/journal.pone.0261312

About Authors

  • Yuriy I. Buziashvili, Dr. Med. Sci., Professor, Academician of the Russian Academy of Sciences, Head of the Clinico-Diagnostic Department; ORCID
  • Elmira U. Asymbekova, Dr. Med. Sci., Leading Researcher; ORCID
  • Elvina F. Tugeeva, Dr. Med. Sci., Senior Researcher; ORCID
  • Igor P. Shuvaev, Cand. Med. Sci., Cardiologist; ORCID
  • Evgeniy P. Golubev, Cand. Med. Sci., Cardiovascular Surgeon; ORCID
  • Firdavsdzhon R. Akildzhonov, Postgraduate; ORCID

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery